Chemotherapy for metastatic castration-sensitive prostate cancer

International Journal of Urology

Volumn 23, Issue 9, 2016, Pages 726-733

  Parimi, Sunil ^a   Chi, Kim N ^a,b  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b Vancouver Prostate Center   (Canada)

Author keywords

castration sensitive; chemotherapy; docetaxel; metastatic; prostate cancer

Indexed keywords

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; DOCETAXEL;

CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CASTRATION; CASTRATION RESISTANT PROSTATE CANCER; CASTRATION SENSITIVE PROSTATE CANCER; DISEASE COURSE; DRUG EFFICACY; HUMAN; MALE; METASTASIS; PATIENT SELECTION; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

EID: 84985038369     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/iju.13148     Document Type: Review

References (51)

1. International Agency for Research on Cancer. Prostate cancer: estimated incidence, mortality and prevalence worldwide in 2012. 2012. [Cited 22 Feb 2016.] Available from URL: http://globocan.iarc.fr/old/FactSheets/cancers/prostate-new.asp
2. Wu JN, Fish KM, Evans CP, Devere White RW, Dall'Era MA. No improvement noted in overall or cause-specific survival for men presenting with metastatic prostate cancer over a 20-year period. Cancer 2014; 120: 818–23.
3. Huggins C, Hodges CV. Studies on prostate cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941; 1: 293–7.
4. Huggins C, Stevens Jr RE, Hodges CV. Studies on prostatic cancer. II. The effects of castration on advanced carcinoma of the prostategland. Arch. Surg. 1941; 43: 209–23.
5. Hellerstedt BA, Pienta KJ. The current state of hormonal therapy for prostate cancer. CA Cancer J. Clin. 2002; 52: 154–79. doi:10.3322/canjclin.52.3.154.
6. Shafi AA, Yen AE, Weigel NL. Androgen receptors in hormone-dependent and castration-resistant prostate cancer. Pharmacol. Ther. 2013; 140: 223–38.
7. Attard G, Cooper CS, de Bono JS. Steroid hormone receptors in prostate cancer: a hard habit to break? Cancer Cell 2009; 16: 458–62.
8. Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 2004; 351: 1502–12.
9. Ryan CJ, Smith MR, de Bono JS et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N. Engl. J. Med. 2013; 368: 138–48.
10. Beer TM, Armstrong AJ, Rathkopf DE et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N. Engl. J. Med. 2014; 371: 424–33.
11. Parker C, Nilsson S, Heinrich D et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N. Engl. J. Med. 2013; 369: 213–23.
12. De Bono JS, Oudard S, Ozguroglu M et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376: 1147–54.
13. Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 2010; 363: 411–22.
14. Saad F, Gleason DM, Murray R et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J. Natl Cancer Inst. 2002; 94: 1458–68.
15. Saad F, Gleason DM, Murray R et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J. Natl Cancer Inst. 2004; 96: 879–82.
16. Fizazi K, Carducci M, Smith M et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011; 377: 813–22.
17. Smith MR, Halabi S, Ryan CJ et al. Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (Alliance). J. Clin. Oncol. 2014; 32: 1143–50.
18. Sweeney CJ, Chen YH, Carducci M et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N. Engl. J. Med. 2015; 373: 737–46.
19. Noguchi M, Noda S, Yoshida M et al. Chemohormonal therapy as primary treatment for metastatic prostate cancer: a randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist. Int. J. Urol. 2004; 11: 103–9.
20. Pummer K, Lehnert M, Stettner H, Hubmer G. Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer. Eur. Urol. 1997; 32(Suppl. 3): 81–5.
21. Murphy GP, Beckley S, Brady MF et al. Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone. Cancer 1983; 51: 1264–72.
22. Millikan RE, Wen S, Pagliaro LC et al. Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer. J. Clin. Oncol. 2008; 26: 5936–42.
23. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat. Rev. Cancer 2004; 4: 253–65.
24. Sanofi-Aventis U.S. LLC. Jevtana prescribing information. 2010. [Cited 19 Mar 2016.] Available from URL: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/201023lbl.pdf
25. Kingston DG. Tubulin-interactive natural products as anticancer agents. J. Nat. Prod. 2009; 72: 507–15.
26. Omlin A, Sartor O, Rothermundt C et al. Analysis of side effect profile of alopecia, nail changes, peripheral neuropathy, and dysgeusia in prostate cancer patients treated with docetaxel and cabazitaxel. Clin. Genitourin. Cancer. 2015; 13: e205–8.
27. Darshan MS, Loftus MS, Thadani-Mulero M et al. Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. Cancer Res. 2011; 71: 6019–29.
28. Pienta KJ. Preclinical mechanisms of action of docetaxel and docetaxel combinations in prostate cancer. Semin. Oncol. 2001; 28(4 Suppl 15): 3–7.
29. Eigl BJC, Eggener SE, Baybik J et al. Timing is everything: preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer. Clin. Cancer Res. 2005; 11: 4905–11.
30. Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. 2004; 351: 1513–20.
31. Gravis G, Fizazi K, Joly F et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, Open-label, Phase 3 trial. Lancet Oncol. 2013; 14: 149–58.
32. Gravis G, Boher JM, Joly F et al. Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 trial. Eur. Urol. 2015. doi: 10.1016/j.eururo.2015.11.005.
33. Glass TR, Tangen CM, Crawford ED, Thompson I. Metastatic carcinoma of the prostate: identifying prognostic groups using recursive partitioning. J. Urol. 2003; 169: 164–9.
34. James ND, Sydes MR, Clarke NW et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 2016; 387: 1163–77.
35. Tucci M, Bertaglia V, Vignani F et al. Addition of docetaxel to androgen deprivation therapy for patients with hormone-sensitive metastatic prostate cancer: a systematic review and meta-analysis. Eur. Urol. 2016; 69: 563–73.
36. Riley RD, Lambert PC, Abo-Zaid G. Meta-analysis of individual participant data: rationale, conduct, and reporting. BMJ 2010; 340: c221.
37. Parker C, Gillessen S, Heidenreich A et al. Cancer of the prostate: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2015; 26(Suppl 5): v69–77.
38. European Association of Eurology. Prostate Cancer. 2016. [Cited 8 Mar 2016.] Available from URL: http://uroweb.org/guideline/prostate-cancer/#6_6
39. Miyamoto S, Ito K, Miyakubo M et al. Impact of pretreatment factors, biopsy Gleason grade volume indices and post-treatment nadir PSA on overall survival in patients with metastatic prostate cancer treated with step-up hormonal therapy. Prostate Cancer Prostatic. Dis. 2012; 15: 75–86.
40. Dorff TB, Crawford ED. Management and challenges of corticosteroid therapy in men with metastatic castrate-resistant prostate cancer. Ann. Oncol. 2013; 24: 31–8.
41. Sartor O, Weinberger M, Moore A, Li A, Figg WD. Effect of prednisone on prostate-specific antigen in patients with hormone-refractory prostate cancer. Urology 1998; 52: 252–6.
42. Rosenthal SA, Bae K, Pienta KJ et al. Phase III multi-institutional trial of adjuvant chemotherapy with paclitaxel, estramustine, and oral etoposide combined with long-term androgen suppression therapy and radiotherapy versus long-term androgen suppression plus radiotherapy alone for high-risk prostate cancer: preliminary toxicity analysis of RTOG 99-02. Int. J. Radiat. Oncol. Biol. Phys. 2009; 73: 672–8.
43. Patel AR, Sandle HM, Pienta KJ. Radiation Therapy Oncology Group 0521: a phase III randomized trial of androgen suppression and radiation therapy versus androgen suppression and radiation therapy followed by chemotherapy with docetaxel/prednisone for localized, high-risk prostate cancer. Clin. Genitourin. Cancer 2005; 4: 212–4.
44. Kumar P, Perrotti M, Weiss R et al. Phase I trial of weekly docetaxel with concurrent three-dimensional conformal radiation therapy in the treatment of unfavorable localized adenocarcinoma of the prostate. J. Clin. Oncol. 2004; 22: 1909–15.
45. Perrotti M, Doyle T, Kumar P et al. Phase I/II trial of docetaxel and concurrent radiation therapy in localized high risk prostate cancer (AGUSG 03-10). Urol. Oncol. 2008; 26: 276–80.
46. Sanfilippo NJ, Taneja SS, Chachoua A, Lepor H, Formenti SC. Phase I/II study of biweekly paclitaxel and radiation in androgen-ablated locally advanced prostate cancer. J. Clin. Oncol. 2008; 26: 2973–8.
47. Hussain M, Smith DC, El-Rayes BF et al. Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locally advanced prostate cancer. Urology 2003; 61: 774–80.
48. Fizazi K, Faivre L, Lesaunier F et al. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial. Lancet Oncol. 2015; 16: 787–94.
49. Morris MJ, Hilden P, Gleave ME et al. Efficacy analysis of a phase III study of androgen deprivation therapy (ADT) +/− docetaxel (D) for men with biochemical relapse (BCR) after prostatectomy. J. Clin. Oncol. 2015; 33(Suppl): abstr 5011.
50. Sandler HM, Hu C, Rosenthal SA et al. A phase III protocol of androgen suppression (AS) and 3DCRT/IMRT versus AS and 3DCRT/IMRT followed by chemotherapy (CT) with docetaxel and prednisone for localized, high-risk prostate cancer (RTOG 0521). J. Clin. Oncol. 2015; 33(Suppl): abstr LBA5002.
51. Ito K. Prostate cancer in Asian men. Nat. Rev. Urol. 2014; 11: 197–212.